BRCA2 and glioblastoma: To test whether this result was pertinent to chemotherapy agents used against glioblastomas, FANCD1/BRCA2 expression was silenced using siRNA in A172 glioblastoma cells, and clonogenic survival assays and MTS assays were then performed with these cells.